At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 220 enrolled
Drug / intervention
INO-4500 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana
In Brief
A Phase 1 clinical trial evaluating INO-4500, CELLECTRA™ 2000, and 1 other intervention for Lassa Fever. Completed, enrolled 220 participants across 1 site.
Detailed Summary
This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000 device in healthy volunteers in Ghana.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLassa Fever
CountriesGhana
CollaboratorsCoalition for Epidemic Preparedness Innovations
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJan 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedSep 17, 2019
Enrollment StartJan 27, 2021
Primary CompletionOct 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.8 years ago
Interventions
INO-4500drug
INO-4500 will be administered ID on Day 0 and Week 4.
CELLECTRA™ 2000device
EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
Placebodrug
Placebo will be administered ID on Day 0 and Week 4.